Clinical trials: Obstructive Lung Disease
Chronic Obstructive Pulmonary Disease
Post Marketing Surveillance of Roflumilast in Korea
The purpose of this study is to evaluate the safety and efficacy of roflumilast in the real-use conditions with its registered indications.
- Trial name
- NCT02068456
- Testing
- Roflumilast
- Where
- South Korea
- Volunteers
- 1,837 people
- Sponsor
- AstraZeneca
Dyspnea, Chronic Obstructive Pulmonary Disease
The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)
Investigators are studying how a device called The Lung Master device can help people breathe better. The investigational device increases the amount of air our lungs can hold, which is important for overall lung health.
- Conditions
- Dyspnea, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT06524856
- Testing
- Lung Master (Pulmonary Exerciser)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Music During Pulmonary Rehabilitation for Patients With COPD
This study is aimed at determining whether listening to music during exercise will improve health-related outcomes for individuals with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02980575
- Testing
- Music, Exercise
- Where
- 2 sites in Australia, Canada
- Volunteers
- 58 people
- Sponsor
- West Park Healthcare Centre
Asthma
Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects
A combination of the corticosteroid GW685698X and the long-acting ß2-agonist GW642444M is being developed for once daily administration for the maintenance treatment of asthma and COPD.
- Trial name
- NCT00538057
- Testing
- GW685698X & GW642444M
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Graft Versus Host Disease
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
The purpose of this research study is to determine the effectiveness of bortezomib (Velcade) plus prednisone for treating chronic graft versus host disease (cGVHD) and the safety of this drug combination in this patient…
- Trial name
- NCT00815919
- Testing
- bortezomib, Prednisone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Obstructive Pulmonary Disease (COPD)
Transnasal Insufflation (TNI) and Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine wether transnasal insufflation as an alternate form of breathing support for COPD patients will lead to improvement of their medical condition.
- Trial name
- TNICOPD (NCT01090544)
- Testing
- Nasal Insufflation
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Helios Klinik Ambrock
Asthma, Bronchiectasis
Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung Disease
Chronic respiratory diseases (CRDs) affect the airways and other structures of the lungs and thereby lead to ventilation inhomogeneity. The most common CRDs in children are asthma, bronchiectasis and cystic fibrosis (CF).
- Conditions
- Asthma, Bronchiectasis, Cystic Fibrosis
- Trial name
- NCT02950116
- Testing
- Perform three multiple breath nitrogen washout tests (N2-MBW-test)
- Where
- Belgium
- Volunteers
- 27 people
- Sponsor
- Universitair Ziekenhuis Brussel
Pulmonary Disease, Chronic Obstructive
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.
- Trial name
- NCT01559116
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Asthma
Breathing Exercises for Asthma
Despite the advances in pharmacological therapy for asthma, there has been an increasing worldwide interest in alternative therapies for asthma.
- Trial name
- NCT02151422
- Testing
- Breathing exercise
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Asthma
Behavioral Intervention to Increase Physical Activity in Patients With Asthma
The health benefits of physical activity (PA) are well documented and include improving in cardiovascular, obesity, mental health and all-cause mortality.
- Trial name
- NCT03705702
- Testing
- Education Program, Behavioral intervention
- Where
- Brazil
- Volunteers
- 46 people
- Sponsor
- University of Sao Paulo General Hospital
Bronchiectasis, Microbial Colonization
Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease
Exacerbations, in particular during chronic Pseudomonas aeruginosa (PA) infection, are very important in the prognosis of patients with non-cystic fibrosis bronchiectasis (BE).
- Conditions
- Bronchiectasis, Microbial Colonization, Pseudomonas Aeruginosa, Biofilm
- Trial name
- NCT04803695
- Testing
- Microbial biofilm diagnose
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Hospital Clinic of Barcelona
Chronic Graft Versus Host Disease
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Participants will be randomized 1:1 to receive either belumosudil or Best Available Therapy (BAT), with stratification based on baseline cGVHD severity as defined by the 2014◦NIH consensus criteria (moderate versus severe), use…
- Trial name
- NCT07771439
- Testing
- Belumosudil, Best available therapy (BAT)
- Volunteers
- 356 people
- Sponsor
- Sanofi
Asthma
SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults
This study will compare during 12 weeks, two treatment strategies for Initial Maintenance Therapy : fluticasone propionate alone or the salmeterol/fluticasone propionate combination in adults with moderate persistent asthma
- Trial name
- NCT00461500
- Testing
- Salmeterol xinafoate/fluticasone propionate combination, Fluticasone propionate
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Bronchial Asthma
Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhaler in patients with bronchial…
- Trial name
- NCT07324707
- Testing
- PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days, Fluticasone Propionate Inhaled Aerosol 200 μg per day for 28 days
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Palo Alto Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to compare the bronchodilator efficacy and safety of once daily dosing of tiotropium inhalation capsules (18 ?g) and Atrovent? MDI (2 puffs of ipratropium bromide 20 ?g four times daily) in patients…
- Trial name
- NCT00239434
- Testing
- tiotropium inhalation powder capsule, ipratropium bromide Metered Dose Inhaler
- Where
- 6 sites in China
- Volunteers
- 200 people
- Sponsor
- Boehringer Ingelheim
Interstitial Lung Disease, Obstructive Sleep Apnea
Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD
The purpose of this study is to evaluate whether biomarkers of lung epithelial and endothelial injury are associated with obstructive sleep apnea (OSA) and interstitial lung disease (ILD).
- Trial name
- NCT03901534
- Testing
- Continuous positive airway pressure (CPAP) therapy, Nox A1 Recorder
- Where
- 2 sites in United States
- Volunteers
- 2,021 people
- Sponsor
- Columbia University
COPD, Pulmonary Hypertension
Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures
The investigators are interested in studying how Pulmonary Hypertension occurs. A substance called 'apelin', that naturally occurs in the body has been shown to have an important role in heart disease.
- Trial name
- NCT02129309
- Testing
- Forearm plethysmography, Haemodynamic studies
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Chronic Obstructive Pulmonary Disease
A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to establish the prevalence of comorbidities in Italian patients with chronic bronchitis with at least 2 exacerbations per year, and to document the appropriateness of instrumental diagnostic tests…
- Trial name
- PREFER (NCT02100332)
- Where
- Italy
- Volunteers
- 860 people
- Sponsor
- AstraZeneca
COPD
Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD
This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7 days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003 compared with that of Placebo MDI on…
- Trial name
- NCT02685293
- Testing
- GFF MDI (PT003)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pearl Therapeutics, Inc.